Observational study on chronic kidney disease in children
Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)
This study looks at how chronic kidney disease affects children's health and growth to see what factors might lead to kidney problems as they grow up.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1300 (estimated) |
| Ages | 6 Months to 22 Years |
| Sex | All |
| Sponsor | Johns Hopkins Bloomberg School of Public Health Academic / other |
| Drugs / interventions | trastuzumab, chemotherapy |
| Locations | 2 sites (Kansas City, Missouri and 1 other locations) |
| Trial ID | NCT00327860 on ClinicalTrials.gov |
What this trial studies
The Chronic Kidney Disease in Children Prospective Cohort Study (CKiD) is an observational study aimed at understanding the risk factors for decline in kidney function among children with chronic kidney disease (CKD). Conducted by a collaboration of prominent institutions, the study collects data on various health outcomes, including cardiovascular health, neurocognitive function, and growth failure. It involves multiple cohorts of children and young adults, with a focus on how CKD impacts their overall health and transition to adult care. The study has been ongoing since 2003 and aims to provide insights that could improve management and outcomes for affected children.
Who should consider this trial
Good fit: Ideal candidates for this study are children aged 1 to 22 years with chronic kidney disease who are regularly seen by a pediatric nephrologist.
Not a fit: Patients with solid organ transplants, recent cancer treatment, or HIV may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management strategies for children with chronic kidney disease, potentially enhancing their long-term health outcomes.
How similar studies have performed: Other studies focusing on chronic kidney disease in children have shown promising results, indicating that this approach is supported by previous research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 1 and 16 years (before 17th birthday) for Cohorts 1 and 2; age between 6 months and 16 years (before 17th birthday) for Cohort 3; age between 16 to 22 years (before 23rd birthday) for Cohort 4 * Estimated (based on SCr) Schwartz GFR between 30 and 90 ml/min\|1.73m2 for Cohort 1 OR an estimated GFR between 45 and 90 ml/min\|1.73m2 based on the updated Schwartz formula for Cohort 2; an estimated GFR ≤60 based on the CKiD Under 25 estimating equation (U25eGFR) OR KRT experience (dialysis or transplant) for Cohort 4 * Willingness and ability to provide informed consent and assent * For Cohort 3, children with non-glomerular diagnosis and duration of kidney disease less than 5 years will be enrolled. Exclusion Criteria: * Solid organ (other than kidney), bone marrow or stem cell transplantation * Cancer diagnosis and receiving treatment or within 12 months post completion of treatment * Ongoing monitoring for cardiotoxic effects of prior chemotherapy or targeted cancer therapies (e.g., anthracyclines, trastuzumab) * HIV infection with detectable viral load despite current antiretroviral therapy * Current pregnancy or pregnancy within past twelve months * Inability to complete major data collection procedures * Not fluent in English or Spanish * Plans to move out of area of any participating CKiD site (families can be transferred to another CKiD site if the family moves) * Existing moderate to severe congenital structural heart disease * Genetic syndromes involving the central nervous system (e.g., Downs syndrome) * History of severe to profound intellectual disability (i.e., Intelligence Quotient (IQ)\<40, significant impairment in adaptive function and/or inability to independently execute self-care skills) * For cohort 3, children who are expected to receive renal replacement therapy within 6 months of date of enrollment will not be recruited
Where this trial is running
Kansas City, Missouri and 1 other locations
- Children's Mercy Kansas City — Kansas City, Missouri, United States (Recruiting)
- The Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States (Recruiting)
Study contacts
- Principal investigator: Susan Furth, MD, PhD — Children's Hospital of Philadelphia
- Study coordinator: Susan Furth, MD, PhD
- Email: FurthS@email.chop.edu
- Phone: 215-590-2449
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.